- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01924793
An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection (PIV)
This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection.
All subjects will have additional PK and Immunogenicity blood samples collected.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will investigate the safety, tolerability, clinical and virologic effect of DAS1814 for the treatment of PIV infections in up to 60 immunocompromised patients with no other treatment options.
Eligible immunocompromised patients positively diagnosed with PIV infection will receive DAS181 by DPI or Nebulized formulation.
DPI: 10 mg DAS181 will be administered for seven (7) consecutive days for up to a total cumulative dose of 70mg.
Nebulized: DAS181 F02 formulation in solution will be administered for seven (7) consecutive days for up to a total cumulative dose of 28.9 mg.
Assessment of viral shedding and viral resistance testing will be performed on collected viral load samples. Blood samples will be obtained to evaluate safety at each scheduled visit.
Routine safety monitoring (including Adverse Event (AE) reporting, clinical laboratory tests, vital signs, electrocardiogram (ECG) and )2 levels) will be conducted in all subjects. A final safety assessment will occur at Day 28 (+/- 2 days) after enrollment/first dose of study drug. Survival, diary cards, and quality of life will be collected at Day 60 and 90. PK will be collected at each visit on all subjects from baseline/visit 2 to visit 11/Day 28. Immunogenicity samples will be collected at selected time points in all subjects.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope
-
Orange, California, United States, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, United States, 94305
- Stanford University Medical Center
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
-
Indiana
-
Indianapolis, Indiana, United States, 42367
- Indiana Blood and Marrow Transplantation
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Cancer Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- John Hopkins University School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham & Women's Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota, School of Medicine
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
-
New York
-
New York, New York, United States, 10021
- Weill Cornell Medical College/New York Presbyterian Hospital
-
New York, New York, United States, 10065
- Weill Cornell Medical College-Peds
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University Wexner Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Md Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
Seattle, Washington, United States, 98109-1024
- Fred Hutchinson Cencer Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥12 years
- Able to provide informed consent or child assent with parental consent
Immunocompromised, as defined by one of the following:
- Allogeneic hematopoietic cell transplantation (HCT)
- Lung or lung-heart transplantation
- Patients treated with chemotherapy for hematologic malignancies or autologous HCT
Confirmed Parainfluenza virus by nasopharyngeal swab or tracheal aspirate for one of the following:
- Respiratory virus panel
- DFA
- Qualitative/quantitative RT-PCR test for parainfluenza virus performed at the local laboratory (a confirmatory PCR test will be done at the central lab but is not required to start the patient on study).
Female subjects of child-bearing potential who are capable of conception must be:
post-menopausal (one year or greater without menses), surgically incapable of childbearing, or practicing two effective methods of birth control. Acceptable methods include intrauterine device, spermicide, barrier, male partner surgical sterilization and hormonal contraception. A female subject must agree to practice two acceptable methods of birth control during the 28 day study period. Abstinence is not an acceptable method of contraception. All reproductive female subjects must have a negative serum pregnancy test during the screening visit.
- Male subjects must agree to use medically accepted form of contraception during the 28 day study period.
Exclusion Criteria:
- Psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the principal investigator, would affect patient safety and/or compliance.
- Any significant finding in the patient's medical history or physical examination that, in the opinion of the investigator, would affect patient safety, ability to use the dry powder inhaler or compliance with the dosing schedule.
- Subjects currently treated with oral, aerosolized or IV ribavirin
- Subjects taking any investigational drug used to research or treat PIV
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Formulation of DAS181-F02 Dry Powder in Bulk
The DAS181-F02 nebulized formulation includes 10mL of normal saline to prepare a liquid solution referred to as DAS181-F02 nebulized. Dry Powder Inhaled Dose: Non-ventilated subjects, capable of using a cyclohaler, will be treated by Dry Powder Inhalation. Each subject will receive a targeted daily dose of 10mg for 7 days for a total of 70mg of DAS181-F02. If a subject requires ventilation, the subject will be allowed to continue dosing following the Nebulized formulation instruction. |
Administered via DPI
|
Experimental: Nebulized Formulation Inhaled Dose
Subjects unable to use the Dry Powder Inhaler (as determined by site Investigator) on continuous positive airway pressure (CPAP), Bi-level positive airway pressure (BIPAP) or requiring mechanical ventilation will be treated by Nebulized formulation. The subject will remain on the nebulized formulation for the duration of the study regardless of ventilation status. DAS-F02 10 mg will be utilized to prepare the nebulized solution per the Study Reference Manual. Multiple methods (T piece, face mask, direct to ET tube) will be allowed for the nebulized dose administration. Detailed specification for nebulized dose administration will be defined in the Study Reference Manual. |
Administered via Nebulizer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cumulative incidence and severity of AEs, SAEs, and lab abnormalities as a measure of safety and tolerability.
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects with PIV viral load reduction at Day 28
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Ron Moss, MD, CEO, Ansun Biopharma, Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DAS181-2-06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parainfluenza
-
ModernaTX, Inc.Active, not recruitingHuman Metapneumovirus and Human Parainfluenza InfectionUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Parainfluenza Virus 2United States
-
MedImmune LLCCompletedHealthyUnited States, Australia, Spain, Germany, Canada, Finland, South Africa, Brazil, Israel
-
National Institute of Allergy and Infectious Diseases...WithdrawnParainfluenza Infection
-
National Institute of Allergy and Infectious Diseases...CompletedParainfluenza Virus 3, HumanUnited States, Puerto Rico
-
MedImmune LLCCompleted
-
ModernaTX, Inc.CompletedHuman Metapneumovirus and Human Parainfluenza InfectionUnited States
-
MedImmune LLCCompletedRespiratory Syncytial Virus Infections | Parainfluenza InfectionsUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedHemorrhagic Fever, EbolaUnited States
-
National Institute of Allergy and Infectious Diseases...Suspended
Clinical Trials on DAS181-F02 Dry Powder in Bulk
-
Ansun Biopharma, Inc.Completed
-
Ansun Biopharma, Inc.National Institutes of Health (NIH)Completed
-
Ansun Biopharma, Inc.National Institutes of Health (NIH)CompletedBronchiectasis | AsthmaUnited States
-
Lung Therapeutics, IncRecruitingIdiopathic Pulmonary FibrosisUnited States, United Kingdom, Germany
-
Medisol Development Kft.University of Debrecen; St. Borbala Hospital; Pest County Pulmonology Hospital; Medical Centre Hungarian Defence Forces and other collaboratorsActive, not recruiting
-
Diamyd Therapeutics ABCompletedType 1 DiabetesSweden
-
Institut National de la Santé Et de la Recherche...Terminated
-
University of California, Los AngelesDey, L.P.WithdrawnChronic Obstructive Pulmonary Disease | Emphysema | COPD | Chronic BronchitisUnited States